Cody Parsons, APh, PharmD, BCCCP, says protected pharmacist access lets patients with heart failure be seen more often than typical clinic visits allow.
|Videos|October 21, 2013
Treatment of Chronic Pain in Children
Sherilyn Driscoll, MD, a pediatrics physiatrist at the Mayo Clinic, discusses how treatment of chronic pain in children has changed.
Advertisement
In this video, Sherilyn Driscoll, MD, a pediatrics physiatrist at the Mayo Clinic, discusses how treatment of chronic pain in children has changed. Rather than looking at pain as always a symptom of an underlying disorder, many physicians are instead focusing on and treating the pain itself.
Advertisement
Related to this article
October’s pain management coverage examined postoperative suzetrigine, pharmacist follow-up for cancer-related neuropathic pain, constipation prevention, and counseling patients concerned about prescribed opioids.
The evidence for GLP-1 receptor agonists keeps growing, while access for low-income patients keeps narrowing.
Specialty pharmacists can help patients with cancer weigh the benefits and risks of GLP-1 receptor agonists as use expands and new evidence emerges.
Pharmacists can work alongside dermatologists, nurses, and other health care professionals to help answer skin care–related questions and help patients understand trial outcomes.
Early metformin may curb insulin starts in gestational diabetes, while a separate analysis ties a history of the condition to advanced CKM syndrome.
Pharmacy Times previews enlicitide, survodutide, diet and heart failure risk, and pharmacist-led HF care ahead of the AHA Scientific Sessions in Chicago.
Expected in the first half of 2028, the planned separation would create a stand-alone retail pharmacy company with nearly 30,000 pharmacists.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Understanding Kratom: Pharmacology, Safety, and Regulation
2
GLP-1 Receptor Agonists and Cancer: Considerations for Specialty Pharmacists
3
What Drives First-Line Immunotherapy Selection in NSCLC? Data, Payers, and Habit
4
Frontline Immunotherapy Options in NSCLC: Are Checkpoint Inhibitors Interchangeable?
5